In systematic reviews that evaluated concerns related to diabetes mellitus, the PCSK9 inhibitors were not associated with the risk of new-onset diabetes and adverse events of diabetes mellitus [7, 8]. This evidence concerns the gene PCSK9 and diabetes mellitus.